About Dr. Joel Winner, M.D.

Joel Winner, M.D. originally worked as a consultant psychiatrist at the Mayo Clinic as part of the Genetic Expression and Neuropsychiatric Evaluation (GENE) Team. His focus was both research and clinical work in pharmacogenomics, though he worked in various clinical environments at Mayo including the Mood Disorder Unit, the psychiatric inpatient unit, and the consultant outpatient clinic.  He also previously worked as the founding medical director of AssureX Health, Inc.  He has extensively written and presented clinical research throughout these various endeavors.  He subsequently founded a private practice in Boulder, Colorado where he specializes in anxiety, perfectionism, obsessive, and family systems issues. His practice is a combination of family systems therapy, Acceptance and Commitment Therapy (ACT), exposure and response prevention tenets (ERP), and pharmacogenomic-informed medication management. He has been appointed as assistant clinical professor at the University of Hawaii department of psychiatry for his ongoing work teaching genetic education to psychiatry residents.  Dr. Winner serves on the national advisory board for the John E. Herman treatment center affiliated with the Mayo Clinic.

Dr. Winner is board certified in general psychiatry by the American Board of Neurology and Psychiatry. 

• Fields E, Lorenz R, Winner J. Use of combinatorial pharmacogenomic testing in two casses from community psychiatry. Dovepress. August 2016
• Winner J, Dechairo B. Combinatorial versus individual gene pharmacogenomic testing in mental health: A perspective on context and implications on clinical utility. Yale Journal of Biology and Medicine. November 2015.
• Winner J, Carhart J, Altar CA, Goldfarb S, Allen J, Lavezzari G, Parsons K, Marshak A,  Garavaglia S, Dechairo B. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a one year prospective evaluation. Current Medical Research and Opinion. July 2015.
• Altar CA, Carhart J, Allen J, Hall-Flavin D, Winner J, Dechairo B. Clinical Utility of Combinatorial Pharmacogenomics-Guided Antidepressant Therapy: Evidence from Three Clinical Studies. Molecular Neuropsychiatry. April 2015.
• Benitez J, Jablonski M, Allen J, Winner J. The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes. Applied and Translational Genomics. March 2015.
• Altar CA, Carhart J, Allen J, Hall-Flavin D, Dechairo B, Winner J. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics Journal. Feb 2015.
• Winner J. Pharmacogenomic Treatment. Today's Geriatric Medicine. Support. Vol. 7 No. 4 P. 20. July/Aug 2014.
• Winner J. Pharmacogenomics in Clinical Practice. Missouri Psychiatry. Newsletter of the Missouri Psychiatric Association 3rd Quarter, 4-5. 2013.
• Winner J, Carhart J, Altar CA, Allen J, Dechairo B. A Prospective, Randomized, Double-Blind Study Assessing the Clinical Impact of Pharmacogenomic Testing for Major Depressive
• Disorder. Discovery Medicine. Nov 2013. Hall-Flavin D, Winner J, Allen J, Carhart J, Proctor B, Snyder K, Drews M, Eisterhold L, Biernacka J, Geske J, Mrazek D. Utility of Integrated Pharmacogenomic Testing to Support the Treatment of Major Depressive Disorder in a Psychiatric Outpatient Setting. Pharmacogenetics and Genomics. 2013.
• Winner J, Allen J, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression in a staff model health management organization. Translational Psychiatry. March 2013.
• Hall-Flavin D, Winner J, Allen J, Jordan J, Nesheim R, Snyder K, Drews M, Eisterhold L, Biernacka J, Mrazek D. Using a pharmacogenomic algorithm to guide the treatment of depression. Translational Psychiatry. Oct 2012.
• Winner J, Allen J, Lorenz J, Altar CA. Cases that test your skills: Overwhelmed by side effects. Current Psychiatry. Vol. 11, No. 6 (p54-58). June 2012
• Winner J. Pharmacogenetics: Using the genome to help guide medication choice and dosing.  Principles and Practice of Geriatric Psychiatry, 2nd edition. In Agronin, M & Maletta, G, Lippincott, Williams & Wilkins, 227-228. 2011.
• Winner J, Goebert D, Matsu C, Mrazek DA. Training in psychiatric genomics in residency: A new challenge. Academic Psychiatry. 34:2 (p115-118). 2010.
• Winner, J. Dementia. Family Medicine Clerkship Guide. In Paulman, P.M., Susman, J.L., Harrison, J.D., Paulman, A.A., Finkelstein, K.M., and Zatechka, R.B. (Eds.), Philadelphia: Elsevier/Mosby. 2005.
• Gross TG, Hinrichs SH, Winner J, Greiner TC, Kaufman S, Sammut PH, Langnas AN. Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low dose chemotherapy. Annals of Oncology. 03/1998;9:1-2. 1998.